{"id":52790,"date":"2023-01-11T13:02:34","date_gmt":"2023-01-11T12:02:34","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/"},"modified":"2023-01-11T13:02:34","modified_gmt":"2023-01-11T12:02:34","slug":"bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/","title":{"rendered":"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium"},"content":{"rendered":"
\n

\n– Company to Host Conference Call on February 14 at 8:00 a.m. ET –<\/i><\/b>\n<\/p>\n

CAMBRIDGE, England, & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc<\/a> (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle<\/i>\u00ae<\/i>) technology, today announced that monotherapy dose escalation results of the ongoing Phase I\/II trial of BT8009, a second-generation BTC\u2122 targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California. On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini (Medical Oncologist, Gustave Roussy) and Dr. Daniel Petrylak (Professor of Medicine and Genitourinary Oncology, Yale School of Medicine) to discuss the data being presented.\n<\/p>\n

\nPoster Presentation Details<\/b>\n<\/p>\n

\nTitle:<\/b> BT8009-100: A Phase I\/II Study of a Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression, Including Urothelial Cancer
\n
Abstract #: <\/b>498
\n
Presenter: <\/b>Capucine Baldini, M.D., on behalf of the BT8009-100 investigators
\n
Session Title: <\/b>Poster Session B: Prostate Cancer and Urothelial Carcinoma
\n
Date\/Time: <\/b>Friday, February 17, 3:30 p.m. to 5:00 p.m.; 8:15 p.m. to 9:15 p.m. ET\n<\/p>\n

\nConference Call Details
\n
<\/b>Bicycle Therapeutics will host a conference call and webcast on Tuesday, February 14, 2023 at 8:00 a.m. ET to review the data being presented. To access the call, please dial (866) 652-5200 (domestic) or (412) 317-6060 (international) and provide the Conference ID 10174689. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com<\/a>.\n<\/p>\n

\nAbout Bicycle Therapeutics
\n
<\/b>Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles<\/i>, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC\u2122) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA\u2122 targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I\/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I\/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
David Borah, CFA
\n
SVP, Capital Markets & Corporate Communications
\n
david.borah@bicycletx.com<\/a>
617-203-8300\n<\/p>\n

\nMedia:<\/b>
Argot Partners
\n
Sarah Sutton
\n
bicycle@argotpartners.com<\/a>
212-600-1902\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Company to Host Conference Call on February 14 at 8:00 a.m. ET – CAMBRIDGE, England, & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that monotherapy dose escalation results of the ongoing Phase I\/II trial of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-52790","format-standard","category-industry"],"yoast_head":"\nBicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Company to Host Conference Call on February 14 at 8:00 a.m. ET – CAMBRIDGE, England, & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that monotherapy dose escalation results of the ongoing Phase I\/II trial of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-11T12:02:34+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\\\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium\",\"datePublished\":\"2023-01-11T12:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/\"},\"wordCount\":475,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/\",\"name\":\"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\\\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-01-11T12:02:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\\\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium - Pharma Trend","og_description":"– Company to Host Conference Call on February 14 at 8:00 a.m. ET – CAMBRIDGE, England, & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that monotherapy dose escalation results of the ongoing Phase I\/II trial of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-11T12:02:34+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium","datePublished":"2023-01-11T12:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/"},"wordCount":475,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/","url":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/","name":"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-01-11T12:02:34+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bicycle-therapeutics-to-present-end-of-dose-escalation-data-from-ongoing-phase-i-ii-study-of-bt8009-at-the-2023-asco-genitourinary-gu-cancers-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52790"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52790\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}